Back to today’s briefing

Story perspectives

FDA Ends Ozempic Shortage, But Costs May Rise

2/23/2025

35 3

Summary

FDA Ends Shortage

The FDA has announced the end of the Ozempic and Wegovy shortage, bringing relief to many. Novo Nordisk's substantial investments have enabled them to meet U.S. demand. However, as compounding pharmacies must stop producing semaglutide by 2025, patients may encounter rising costs, even as overall availability is set to improve.

Summary

Hims & Hers Struggles

The FDA's recent declaration that the shortage of Ozempic and Wegovy is over has sent Hims & Hers Health's stock tumbling by over 20%. Once thriving on compounded versions of these medications, the company now faces a pivotal moment, seeking to pivot its strategy and acquire a peptide manufacturing facility to stay competitive in the weight-loss arena.

1 of 2

FDA Ends Shortage

The FDA has announced the end of the Ozempic and Wegovy shortage, bringing relief to many. Novo Nordisk's substantial investments have enabled them to meet U.S. demand. However, as compounding pharmacies must stop producing semaglutide by 2025, patients may encounter rising costs, even as overall availability is set to improve.

1 / 2